Skip to main content

Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update

In brief

Nasopharyngeal cancer guideline backs risk-tailored chemotherapy and MRI-guided radiotherapy

The updated guideline supports MRI-guided radiotherapy, selected reductions in treatment target areas, and chemotherapy tailored to stage and biologic risk, with gemcitabine-cisplatin or TPF preferred before radiation. Trials show that adding immunotherapy improves disease control, but overall survival results are still immature, so the panel makes no recommendation for routine use; decisions should account for patient preferences and local access.

Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology (Q1)
Published
10 November 2026
Study design
Practice guideline / consensus
Evidence level
Level 1, High (CEBM 1b)
Authors
Yu-Pei Chen, Nofisat Ismaila, Shao Hui Huang, Wei Jiang, Brigette Ma, Robert Haddad, et al.
PMID
43008242
DOI
10.1200/JCO-26-02648

Why clinicians should know about it

Abstract

PURPOSE: To update the 2021 CSCO-ASCO guideline on chemotherapy in combination with radiotherapy for the definitive treatment of non-metastatic nasopharyngeal carcinoma (NPC), incorporating new evidence on radiotherapy techniques and target-volume de-escalation, chemotherapy regimens and their sequencing, adjuvant therapy, and immunotherapy for patients with stage IB-III disease. METHODS: A multidisciplinary Expert Panel reviewed evidence published since the prior guideline, including randomized controlled trials, systematic reviews, meta-analyses, and relevant prospective and retrospective studies. Outcomes of interest included overall survival, failure-free or progression-free survival, locoregional and distant disease control, acute and late toxicities, and patient-reported quality of life. Recommendations were developed using the ASCO guideline development process and Expert Panel consensus. RESULTS: The updated evidence supports: IMRT with image guidance and MRI-based target delineation as core components of definitive treatment; selected response-adapted target delineation following induction chemotherapy; elective nodal de-escalation in appropriately selected patients; risk-adapted chemotherapy sequencing according to stage and biologic risk; cisplatin-based concurrent chemoradiotherapy; gemcitabine-cisplatin (GP) or docetaxel-cisplatin-fluorouracil (TPF) as preferred induction regimens; and selected adjuvant chemotherapy options, including metronomic capecitabine for patients with higher residual post-chemoradiotherapy risk. Several randomized trials evaluating PD-1 inhibitors have demonstrated improved disease-control outcomes, but overall survival data remain immature. RECOMMENDATIONS: This guideline update provides recommendations on radiotherapy technique, dose, imaging, and target delineation; sequencing of additional chemotherapy with radiotherapy; concurrent chemotherapy options; induction chemotherapy regimens and timing; adjuvant chemotherapy options; and the role of immunotherapy. At present, the Panel makes no recommendation for or against routine addition of immunotherapy to induction-concurrent chemoradiotherapy; applicability of the trial evidence, benefits and harms, local approval and access, and patient preferences should guide individualized decisions.Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.